23andMe Holding Co. – NASDAQ:ME

23andMe Holding stock price today

$0.606
-2.69
-81.63%
Financial Health
0
1
2
3
4
5
6
7
8
9

23andMe Holding stock price monthly change

+583.37%
month

23andMe Holding stock price quarterly change

+583.37%
quarter

23andMe Holding stock price yearly change

+265.98%
year

23andMe Holding key metrics

Market Cap
87.59M
Enterprise value
639.76M
P/E
-3.08
EV/Sales
2.07
EV/EBITDA
-2.34
Price/Sales
3.22
Price/Book
1.32
PEG ratio
0.06
EPS
-1.4
Revenue
219.63M
EBITDA
-84.70M
Income
-666.70M
Revenue Q/Q
-30.68%
Revenue Y/Y
-26.66%
Profit margin
-103.07%
Oper. margin
-105.37%
Gross margin
46.01%
EBIT margin
-105.37%
EBITDA margin
-38.57%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

23andMe Holding stock price history

23andMe Holding stock forecast

23andMe Holding financial statements

23andMe Holding Co. (NASDAQ:ME): Profit margin
Jun 2023 60.86M -104.62M -171.9%
Sep 2023 49.99M -75.27M -150.54%
Dec 2023 44.74M -277.97M -621.22%
Mar 2024 64.02M -208.83M -326.16%
23andMe Holding Co. (NASDAQ:ME): Analyst Estimates
2026 276.13M -351M -127.11%
2027 303.24M -232.02M -76.51%
  • Analysts Price target

  • Financials & Ratios estimates

23andMe Holding Co. (NASDAQ:ME): Earnings per share (EPS)
2023-11-08 -0.14 -0.16
2024-02-07 -0.14 -0.17
2024-05-23 -0.15 -0.12
23andMe Holding Co. (NASDAQ:ME): Debt to assets
Jun 2023 871199000 195.70M 22.46%
Sep 2023 801230000 175.97M 21.96%
Dec 2023 608211000 231.02M 37.98%
Mar 2024 395167000 206.64M 52.29%
23andMe Holding Co. (NASDAQ:ME): Cash Flow
Jun 2023 -69.35M -2.69M -114K
Sep 2023 -57.11M -2.77M 1.59M
Dec 2023 -12.06M -2.01M 105K
Mar 2024 -16.99M -2.14M -6.79M

23andMe Holding alternative data

23andMe Holding Co. (NASDAQ:ME): Employee count
Aug 2023 769
Sep 2023 758
Oct 2023 758
Nov 2023 758
Dec 2023 769
Jan 2024 769
Feb 2024 769
Mar 2024 769
Apr 2024 769
May 2024 769
Jun 2024 769
Jul 2024 560

23andMe Holding other data

11.15% -18.78%
of ME is owned by hedge funds
50.55M -84.09M
shares is hold by hedge funds

23andMe Holding Co. (NASDAQ:ME): Insider trades (number of shares)
Period Buy Sel
Jun 2023 0 40894
Jul 2023 0 81788
Aug 2023 0 81788
Sep 2023 0 81980
Oct 2023 0 77096
Nov 2023 0 115644
Dec 2023 0 77096
Jan 2024 0 77096
Feb 2024 0 77096
Mar 2024 0 77096
Apr 2024 0 77096
May 2024 0 38551
Transaction Date Insider Security Shares Price per share Total value Source
Option
HIBBS KATHY L officer: Chief Administrative O..
Class A Common Stock 38,551 $0.42 $16,191
Sale
HIBBS KATHY L officer: Chief Administrative O..
Class A Common Stock 38,551 $0.49 $19,044
Option
HIBBS KATHY L officer: Chief Administrative O..
Stock Option (Right to Buy) 38,551 $0.42 $16,191
Option
HIBBS KATHY L officer: Chief Administrative O..
Class A Common Stock 38,548 $0.42 $16,190
Sale
HIBBS KATHY L officer: Chief Administrative O..
Class A Common Stock 38,548 $0.47 $18,156
Option
HIBBS KATHY L officer: Chief Administrative O..
Stock Option (Right to Buy) 38,548 $0.42 $16,190
Option
HIBBS KATHY L officer: Chief Administrative O..
Class A Common Stock 38,548 $0.42 $16,190
Sale
HIBBS KATHY L officer: Chief Administrative O..
Class A Common Stock 38,548 $0.5 $19,274
Option
HIBBS KATHY L officer: Chief Administrative O..
Stock Option (Right to Buy) 38,548 $0.42 $16,190
Option
HIBBS KATHY L officer: Chief Administrative O..
Class A Common Stock 38,548 $0.42 $16,190
Insider Compensation
Mr. Steven J. Schoch (1959) Chief Financial and Accounting Officer
$582,830
Ms. Kathy L. Hibbs Esq., J.D. (1964) Chief Legal & Regulatory Officer and Sec.
$558,530
Dr. Kenneth J. Hillan (1961) Head of Therapeutics $557,620
Wednesday, 20 November 2024
globenewswire.com
Monday, 18 November 2024
newsfilecorp.com
Tuesday, 12 November 2024
seekingalpha.com
techcrunch.com
fastcompany.com
cnbc.com
marketwatch.com
proactiveinvestors.co.uk
Monday, 11 November 2024
wsj.com
marketwatch.com
reuters.com
globenewswire.com
Thursday, 7 November 2024
globenewswire.com
globenewswire.com
Wednesday, 30 October 2024
globenewswire.com
businessinsider.com
Tuesday, 29 October 2024
cnbc.com
globenewswire.com
Monday, 28 October 2024
globenewswire.com
Wednesday, 23 October 2024
cnbc.com
Sunday, 20 October 2024
247wallst.com
Wednesday, 16 October 2024
globenewswire.com
Friday, 11 October 2024
globenewswire.com
Tuesday, 1 October 2024
globenewswire.com
Monday, 30 September 2024
reuters.com
accesswire.com
Sunday, 29 September 2024
globenewswire.com
Friday, 27 September 2024
accesswire.com
globenewswire.com
Thursday, 26 September 2024
accesswire.com
  • What's the price of 23andMe Holding stock today?

    One share of 23andMe Holding stock can currently be purchased for approximately $0.61.

  • When is 23andMe Holding's next earnings date?

    Unfortunately, 23andMe Holding's (ME) next earnings date is currently unknown.

  • Does 23andMe Holding pay dividends?

    No, 23andMe Holding does not pay dividends.

  • How much money does 23andMe Holding make?

    23andMe Holding has a market capitalization of 87.59M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 19.22% to 219.64M US dollars. 23andMe Holding made a loss 666.7M US dollars in net income (profit) last year or -$0.12 on an earnings per share basis.

  • What is 23andMe Holding's stock symbol?

    23andMe Holding Co. is traded on the NASDAQ under the ticker symbol "ME".

  • What is 23andMe Holding's primary industry?

    Company operates in the Healthcare sector and Medical - Diagnostics & Research industry.

  • How do i buy shares of 23andMe Holding?

    Shares of 23andMe Holding can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are 23andMe Holding's key executives?

    23andMe Holding's management team includes the following people:

    • Mr. Steven J. Schoch Chief Financial and Accounting Officer(age: 66, pay: $582,830)
    • Ms. Kathy L. Hibbs Esq., J.D. Chief Legal & Regulatory Officer and Sec.(age: 61, pay: $558,530)
    • Dr. Kenneth J. Hillan Head of Therapeutics(age: 64, pay: $557,620)
  • How many employees does 23andMe Holding have?

    As Jul 2024, 23andMe Holding employs 560 workers, which is 27% less then previous month and 27% less then previous quarter.

  • When 23andMe Holding went public?

    23andMe Holding Co. is publicly traded company for more then 4 years since IPO on 23 Nov 2020.

  • What is 23andMe Holding's official website?

    The official website for 23andMe Holding is 23andme.com.

  • Where are 23andMe Holding's headquarters?

    23andMe Holding is headquartered at 349 Oyster Point Boulevard, South San Francisco, CA.

  • How can i contact 23andMe Holding?

    23andMe Holding's mailing address is 349 Oyster Point Boulevard, South San Francisco, CA and company can be reached via phone at +65 09386300.

23andMe Holding company profile:

23andMe Holding Co.

23andme.com
Exchange:

NASDAQ

Full time employees:

560

Industry:

Medical - Diagnostics & Research

Sector:

Healthcare

23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.

349 Oyster Point Boulevard
South San Francisco, CA 94080

CIK: 0001804591
ISIN: US90138Q1085
CUSIP: 90138Q108